METH-or MK-801-induced hyperactivity in rats and MK-801-induced PPI deficits in mice. TAK-063 at 0.1 mg/kg did not affect plasma prolactin levels and cataleptic response induced by HAL or OLA in rats. Discussion: PDE10A inhibitors and HAL showed similar patterns of gene regulation in indirect pathway MSNs in mice. Combined treatment with TAK-063 and either HAL or OLA at subeffective doses produced significant antipsychotic-like effects but no augmentation of the plasma prolactin level and cataleptic response. Although further preclinical and clinical studies will be needed, TAK-063 may provide a novel mechanism as a PDE10A inhibitor for use as combination therapy in schizophrenia. Background: Cannabis use can induce acute and long-lasting psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (−)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in modest cannabis users, who represent the majority of recreational users. Methods: Twenty-four healthy men participated in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject, ∆9-THC challenge study.
Women's College Hospital
Background: Weight gain is an extremely common problem in schizophrenia patients and is associated with morbidity and mortality. We conducted a Cochrane meta-analysis to determine the effects of pharmacological interventions aimed at reduction or prevention of weight gain in schizophrenia. Methods: We searched the Cochrane Schizophrenia Group's Trials Register that is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There is no language, date, document type, or publication status limitations for inclusion of records in the register. We also searched reference sections within relevant papers, hand searched key journals, and contacted the first author of each relevant study and other experts to collect further information. We included all double blind randomized controlled trials examining any adjunctive pharmacological intervention for weight loss (treatment) or weight maintenance (prevention) in patients with schizophrenia or schizophrenia-like illnesses. We reliably selected, quality assessed and extracted data from studies. As endpoint and change data were combined in the analysis, mean differences (MD) of the change from baseline were calculated. The primary outcome measure was weight loss. Results: Forty-four randomized controlled trials met the inclusion criteria for this review. Ten studies examined prevention of weight gain while on antipsychotics. Reboxetine may be slightly effective in preventing weight gain (Weight: MD -2.09 kg, 95% CI -3.12 to -1.05; participants = 111; studies = 3; BMI: MD -0.70, 95% CI -1.03 to -0.36; participants = 111; studies = 3) and but the quality of evidence is low as the studies are small and have all been conducted by the same group. We are uncertain about the other agents used in a preventive role because the quality of evidence is very low. Thirty-four studies examined reduction of weight gain with pharmacological interventions. Metformin is effective in bringing about modest weight loss (MD -3.45 kg, 95% CI -4.92 to -1.98 kg; participants = 569; studies = 8; BMI: MD -1.32 kg/m2, 95% CI -1.84 to -0.81 kg/m2; participants = 606; studies = 9). This effect is probably stronger in first episode psychosis (FEP) patients (Weight: MD -5.18 kg, 95% CI -6.22 to -4.14 kg; participants = 214; studies = 3; BMI: MD -1.87 kg/m2, 95% CI -2.19 to -1.56 kg/m2; participants = 214; studies = 3) compared to chronic patients (Weight: MD -2.0 kg, 95% CI -3.0 to -1.0 kg; participants = 355; studies = 5; BMI: MD -0.73 kg/m2, 95% CI -1.04 to -0.42 kg/m2; participants = 392; studies = 6). Metformin probably decreases fasting insulin levels and insulin resistance as well. The frequency of adverse effects did not differ between metformin and placebo groups. Other agents that may reduce weight include aripiprazole, topiramate, H2 antagonists such as nizatidine, and sibutramine but the quality of the evidence is low or very low making the effects uncertain. Importantly, none of the adjunctive treatment strategies result in higher dropout rates. Other than higher reports of anxiety with aripiprazole, none of the adjunctive treatment strategies appear to result in worsening of mental status. Discussion: Accumulating evidence supports the safe use of pharmacological interventions to achieve modest weight loss. Reboxetine may be slightly effective in preventing weight gain while metformin has the most evidence for use as treatment of weight gain in schizophrenia. The small number of studies, small sample size, and short study duration limits interpretation for other agents. Future studies that are adequately powered, with longer treatment duration, will be needed in evaluating the efficacy and safety of interventions for managing weight gain further. Background: Optimal pharmacological efficacy is crucial in first-episode and early-episode schizophrenia and bipolar I disorder. Olanzapine (OLZ) is a highly efficacious antipsychotic indicated for the treatment of schizophrenia and bipolar I disorder. However, the clinical utility of OLZ may be limited by a propensity to cause significant weight gain and increased metabolic side effects, especially for patients early in the course of their illness. ALKS 3831 is composed of a flexible dose of olanzapine (OLZ) and a fixed dose of 10 mg of samidorphan (SAM), formulated as a bilayer tablet. ALKS 3831 has been shown in Phase 1 and Phase 2 studies to result in significantly less weight gain than OLZ while delivering equivalent antipsychotic efficacy. This Phase 3, 12-week study, is designed to evaluate the effect of ALKS 3831 on body weight in young adults early in the course of diagnosis of a serious mental illness, including a schizophreniform, schizophrenia, or bipolar I disorder diagnosis. Methods: This is an international (Austria, Germany, Ireland, Israel, Italy, Poland, Spain, UK, and USA) two-arm, double-blind, active-comparatorcontrolled, multicentre study (planned N=250) that started enrollment in 2017. Key inclusion criteria are a primary diagnosis of schizophreniform disorder, schizophrenia, or bipolar I disorder; a body-mass index (BMI) of ≥18.0 and ≤27.0 kg/m2; and meeting specific criteria for duration of illness and prior antipsychotic exposure. Patients with a bipolar I diagnosis must be in the manic phase. In the US sites, men and women must be aged ≥16 to <40 years at screening, and in Europe, aged ≥18 to <40 years. Exclusion criteria include diagnosis of additional psychiatric conditions and use of prohibited drugs.
S226. A STUDY COMPARING WEIGHT
Results: Patients will be randomised 1:1 to receive either OLZ or ALKS 3831 treatment for 12 weeks. ALKS 3831 (OLZ + SAM) and matched OLZ + placebo (OLZ + PBO) will be provided as bilayer tablets to be taken by mouth once daily and doses will include ALKS 3831 (OLZ/SAM) 5/10 mg, 10/10 mg, 15/10 mg, 20/10 mg, or (OLZ/PBO) 5 mg, 10 mg, 15 mg, or 20 mg. The primary endpoint will be percent change in body weight from baseline to Week 12. Secondary and exploratory endpoints will include the proportion of patients who gain ≥7% and ≥10% of baseline body weight, metabolic parameters (change in fasting lipids and glucose), body composition measured through bioimpedance, clinical global impression, and safety, pharmacokinetic, and pharmacodynamic parameters. Patients will be offered a supportive clinical care programme during the 12-week treatment period, and also receive a daily medication-adherence monitoring and reminder system (via smartphones). Background: Early intervention at the beginning of schizophrenia and related psychotic disorders can get better treatment response. Once symptoms subsided, the majority of patients wish to discontinue medications, yet currently the mainstream opinions still recommend maintenance antipsychotic therapy because non-adherence to medication is the most significant risk factor to predict a relapse. However, recent longitudinal studies assessing patients in community for a longer term found that discontinuation of antipsychotics might not necessarily be parallel to poorer functioning. Also there are studies suggesting a lower percentage of dopamine occupancy by antipsychotic is acceptable in stable patients with psychosis. To elucidate such discrepancies, a hypothetical compromised approach "guided dose reduction, but not aiming at discontinuation" was proposed and an observational clinical trial was initiated since July 2017. Methods: Outpatients with schizophrenia-related psychotic disorders under remitted states will be recruited and randomized into guided dose reduction group (GDR, target n = 80) and maintenance treatment group (MTG1, target n = 40), and those who eligible to dose reduction yet willing to continue medication will serve as a naturalistic observation group (MTG2, target n = 40). Patients in the GDR will reduce no more than 25% of their current dose of antipsychotics and closely monitored every 4 weeks for at least 24 weeks before next dose reduction adjustment. Patients of both MTGs receive treatment as usual. All patients will be followed up for at least 2 years. The main outcomes of interests are differences in relapse rates, personal social performance, quality of life, drug-related adverse reactions, medication satisfaction, and neurocognitive functioning between groups. Patient's actual medication status will be monitored by keeping a log and therapeutic drug monitoring on selective antipsychotics. Patient's demographics and clinical variables will be taken to test whether these variables are related to outcomes during follow-up. Results: Currently 26 patients have participated in this study, including 10 males and 16 females, with a Mean (SD) age 31.8(7) years old. Eleven of them were in GDR group, 10 in MTG1, and 5 in MTG2. Their baseline PANSS scores were 36.9(5.7), 37.4(7.9), 49.2(7.4), CGI-S scores were 1.7(0.6), 1.5(0.7), 2(0), and Personal Social Performance (PSP) scores were 82.2(7.9), 83. 
University of Naples "Federico II"
Background: Treatment Resistant Schizophrenia (TRS) is associated to poor prognosis and highly disabling course. Early detection of the condition is crucial to rapidly provide targeted interventions. The aim of this study was to evaluate whether it may be possible to distinguish TRS from Antipsychotic Responder Schizophrenia (ARS) patients on the basis of a limited number of measurable clinical factors. Methods: 60 out of 182 eligible patients were included. A multistep diagnostic procedure to separate TRS from ARS was then used. Clinical parameters were recorded. Rating scales were administered, including: the Neurological Evaluation Scale (NES); the Positive and Negative Syndrome Scale (PANSS); the Heinrichs' Quality of Life Scale (QLS); the UCSD
